UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe ...

The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC ...

The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ ...

Highly encouraged to read this in Jim Nantz voice Hello friends. Consider a brand. Picture an experience. The Masters, one of ...

Join us for this episode of Global Health Beat, featuring Dr. Richard Bambury as he explores the unique opportunities for ...

Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...

This Blood Cancer Awareness Month, we want to highlight the critical role of patient-centricity in building awareness, ...

Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...

More and more health data is being collected in the real-world about how that medicine works in a wider population than that ...

Less attention has been given to the impact AI can have at the later stages of drug development and on patient access. This ...

Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for a subset of non-small cell lung cancer ...

Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.